These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19396468)

  • 41. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
    Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
    J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Idiopathic nephrotic syndrome in children: from corticosteroids to rituximab].
    Deschênes G
    Arch Pediatr; 2011 Aug; 18(8):843-5. PubMed ID: 21719260
    [No Abstract]   [Full Text] [Related]  

  • 44. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The uncertainty of rituximab and steroid dosing in refractory steroid-resistant nephrotic syndrome.
    Hirano D; Fujinaga S; Nishizaki N
    Clin Nephrol; 2012 Jun; 77(6):510-2. PubMed ID: 22595396
    [No Abstract]   [Full Text] [Related]  

  • 46. Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome.
    Nakamura M; Kanda S; Yoshioka Y; Takahashi C; Owada K; Kajiho Y; Harita Y; Oka A
    CEN Case Rep; 2020 May; 9(2):173-176. PubMed ID: 31970629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroid-dependent nephrotic syndrome.
    Fujinaga S; Hirano D
    Pediatr Nephrol; 2014 Mar; 29(3):491-2. PubMed ID: 24240472
    [No Abstract]   [Full Text] [Related]  

  • 48. Fatal adenoviral hepatitis after rituximab therapy.
    Iyer A; Mathur R; Deepak BV; Sinard J
    Arch Pathol Lab Med; 2006 Oct; 130(10):1557-60. PubMed ID: 17090202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New treatment strategies in idiopathic nephrotic syndrome.
    Ulinski T; Aoun B
    Minerva Pediatr; 2012 Apr; 64(2):135-43. PubMed ID: 22495188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
    Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute respiratory distress syndrome after rituximab infusion.
    Montero AJ; McCarthy JJ; Chen G; Rice L
    Int J Hematol; 2005 Nov; 82(4):324-6. PubMed ID: 16298824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis.
    Bussone G; Kaswin G; de Menthon M; Delair E; Brézin AP; Guillevin L
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):90-2. PubMed ID: 20412711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].
    Kamei K; Okada M; Miyazono A; Sato M; Fujimaru T; Ogura M; Ito S
    Nihon Jinzo Gakkai Shi; 2013; 55(5):947-55. PubMed ID: 23980480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome.
    Hoseini R; Sabzian K; Otukesh H; Zafaranloo N; Panahi P; Rahimzadeh N; Nakhaie S; Akhavan Sepehi M
    Iran J Kidney Dis; 2018 Jan; 12(1):27-32. PubMed ID: 29421774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab in refractory nephrotic syndrome.
    Prytuła A; Iijima K; Kamei K; Geary D; Gottlich E; Majeed A; Taylor M; Marks SD; Tuchman S; Camilla R; Ognjanovic M; Filler G; Smith G; Tullus K
    Pediatr Nephrol; 2010 Mar; 25(3):461-8. PubMed ID: 20033225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia.
    Basse G; Ribes D; Kamar N; Esposito L; Rostaing L
    Clin Nephrol; 2006 Nov; 66(5):395-6. PubMed ID: 17140171
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
    Fujinaga S; Nishino T; Umeda C; Tomii Y; Watanabe Y; Sakuraya K
    Pediatr Nephrol; 2019 Feb; 34(2):353-357. PubMed ID: 30426219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pediatric idiopathic nephrotic syndrome: treatment strategies in steroid dependent and steroid resistant forms.
    Ulinski T; Aoun B
    Curr Med Chem; 2010; 17(9):847-53. PubMed ID: 20156172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
    Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
    Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
    Kolonko A; Piecha G; Więcek A
    Transplant Proc; 2016 Nov; 48(9):3092-3094. PubMed ID: 27932154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.